Endo Pharmaceuticals Holdings Inc. Chief Says He Has $500 Million to Buy Cancer and Urology Products

January 13, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Bloomberg -- Endo Pharmaceuticals Holdings Inc. has a $500 million budget for acquisitions and is seeking health information technology and diagnostic tools for cancer and urology, Chief Executive Officer David Holveck said.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions